CN105250721A - Medicine for treating rheumatoid arthritis and preparation method of medicine - Google Patents
Medicine for treating rheumatoid arthritis and preparation method of medicine Download PDFInfo
- Publication number
- CN105250721A CN105250721A CN201510670431.3A CN201510670431A CN105250721A CN 105250721 A CN105250721 A CN 105250721A CN 201510670431 A CN201510670431 A CN 201510670431A CN 105250721 A CN105250721 A CN 105250721A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- medicine
- rheumatic arthritis
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating rheumatoid arthritis. The medicine comprises a pharmaceutically acceptable carrier/excipient, and the following active ingredients: creeping rostellularia herb, dandelion, dendrobium officinale, black ants, radix aconiti kusnezoffii, herba lycopodii, frankincense, ciderage and fleece-flower root. The medicine is definite in curative effect, lasting in effect, and free of obvious side effects, and has the efficacy of improving physique while conditioning human body function. After a patient takes the medicine, blood circulation in limbs of the patient is accelerated, the medicine reaches joints of an affected limb along with flowing of blood, precipitate in cavities of the joints is absorbed and decomposed by tissues gradually, and unabsorbable viruses existing in the body of the patient can be excreted from the body of the patient under the action of slight sweating of a local part, that is, the rheumatoid arthritis is eradicated. A preparation method of the medicine is simple, convenient to operate, and easy to master.
Description
Technical field
The present invention relates to treatment rheumatism field, particularly a kind of pharmaceutical composition for the treatment of rheumatic arthritis and preparation method thereof.
Background technology
Rheumatic arthritis is a kind of common acute or chronic ICT.Rheumatic arthritis must first talk about rheumatic fever.Before the 50-60 age in last century, rheumatic fever is very general in child, it be a kind of caused by beta hemolytic streptococcus first infect the disease producing autoimmune response afterwards, final infringement endocardium, one of symptom the most outstanding in morbidity is exactly arthritis, feature is extremity large joint symmetry, migrans congestion and swelling pain, in quite over a long time, generally it is called rheumatic arthritis clinically.The rheumatic arthritis onset age is common with 9-17 year, and M-F is suitable.Rheumatic arthritis is common involves large joint (knee joint, elbow joint etc.), does not cause the deformity in joint.Also has the symptom of erythema iris, chorea, carditis.The Drug therapy rheumatoid arthritis effect of prior art is undesirable, or side effect is large.
The information being disclosed in this background technology part is only intended to increase the understanding to general background of the present invention, and should not be regarded as admitting or imply in any form that this information structure has been prior art that persons skilled in the art are known.
Summary of the invention
The object of the present invention is to provide a kind of medicine for the treatment of rheumatic arthritis, thus overcome the shortcoming that existing medication effect is undesirable, side effect is large.
Another object of the present invention is to the preparation method of rheumatoid arthritis agents.
For achieving the above object, the invention provides a kind of medicine for the treatment of rheumatic arthritis, it contains pharmaceutically acceptable carrier or excipient, and following active component: Herba Rostellulariae, Herba Taraxaci, Herba Dendrobii, Formica fusca, Radix Aconiti Kusnezoffii, Herba Lycopodii, Olibanum, Herba polygoni hydropiperis and Radix Polygoni Multiflori.
Preferably, in technique scheme, the medicine of described treatment rheumatic arthritis, it contains pharmaceutically acceptable carrier or excipient, and the active component of following weight ratio: Herba Rostellulariae 5 ~ 10 parts, Herba Taraxaci 1 ~ 5 part, Herba Dendrobii 5 ~ 10 parts, Formica fusca 1 ~ 3 part, Radix Aconiti Kusnezoffii 5 ~ 10 parts, Herba Lycopodii 5 ~ 15 parts, Olibanum 1 ~ 5 part, Herba polygoni hydropiperis 5 ~ 10 parts and Radix Polygoni Multiflori 1 ~ 5 part.
Preferably, in technique scheme, the medicine of described treatment rheumatic arthritis, it contains pharmaceutically acceptable carrier or excipient, and the active component of following weight ratio: Herba Rostellulariae 7 parts, Herba Taraxaci 4 parts, Herba Dendrobii 7 parts, Formica fusca 2 parts, Radix Aconiti Kusnezoffii 6 parts, Herba Lycopodii 9 parts, Olibanum 2 parts, Herba polygoni hydropiperis 8 parts and Radix Polygoni Multiflori 3 parts.
Preferably, in technique scheme, the medicine of described treatment rheumatic arthritis, described pharmaceutical composition also comprises following active component: Herba speranskiae tuberculatae, Radix Glycyrrhizae and parthenocissus.
Preferably, in technique scheme, described pharmaceutical composition also comprises the active component of following weight ratio: Herba speranskiae tuberculatae 5 ~ 15 parts, 1 ~ 5 part, Radix Glycyrrhizae and parthenocissus 2 ~ 8 parts.
Preferably, in technique scheme, the dosage form of described pharmaceutical composition is selected from: mixture, ointment, preparation capable of permeating skin, externally used solution agent, lotion, smear agent, ointment, plaster, paste or patch.
Preferably, in technique scheme, described pharmacy and bromatology can be selected from by carrier: filler, lubricant, fluidizer, effervescent, correctives, coating material or excipient.
A kind of preparation method of medicine of described treatment rheumatic arthritis, by Herba Rostellulariae, Herba Taraxaci, Herba Dendrobii, Formica fusca, Radix Aconiti Kusnezoffii, Herba Lycopodii, Olibanum, Herba polygoni hydropiperis and Radix Polygoni Multiflori mixing, decoct with water 1 ~ 3 hour, decocting liquid filters, filtrate is concentrated into 1.00 ~ 1.10, adds stabilizing agent, mixing leaves standstill, get the supernatant, obtain pharmaceutical composition stock solution.
Preferably, in technique scheme, in described preparation method, decoct with water 2 times, decoct 1 ~ 3 hour at every turn, then twice decoction is obtained filtrate mixing.
Preferably, in technique scheme, described stabilizing agent is one or both in sodium benzoate or steviosin.
The property of medicine of pharmaceutical composition active ingredient medicine of the present invention is as follows:
Herba Rostellulariae: nature and flavor are salty flat, cold.Have heat-clearing and toxic substances removing, dampness removing disappears stagnant, effect of promoting blood circulation and stopping pain.
Herba Taraxaci: heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, inducing diuresis for treating stranguria syndrome.For furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.
Herba Dendrobii: nourishing the stomach of promoting the production of body fluid; Nourishing YIN and clearing away heat; Lung moistening kidney tonifying; The strong waist of improving eyesight.
Formica fusca: control venom and furunculosis swells and ache.Cure mainly rheumatism, rheumatoid arthritis, scapulohumeral periarthritis, ankylosing spondylitis, hemiplegia, cervical spondylosis.
Radix Aconiti Kusnezoffii: expelling wind and removing dampness, antalgic.For anemofrigid-damp arthralgia, arthralgia, trusted subordinate's cold type of pain, colic of cold type is had a pain, narcotic analgesic.
Herba Lycopodii: expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral.For joint aches, joint stuffiness.
Olibanum: promoting blood circulation and stopping pain.For all pains of trusted subordinate, the contracture of muscle arteries and veins, traumatic injury, sore, carbuncle and painful swelling; Externally used detumescence granulation promoting.
Herba polygoni hydropiperis: expelling wind and removing dampness, eliminating stasis to stop pain, removing toxic substances and promoting subsidence of swelling, killing parasites for relieving itching.For dysentery, gastroenteritis, diarrhoea, rheumatic arthritis, treating swelling and pain by traumatic injury, dysfunctional uterine hemorrhage; Venom is controlled in external, skin eczema.
Radix Polygoni Multiflori: can calm the nerves, nourish blood, active, removing toxic substances (preventing the attack (or recurrence) of malaria), eliminating carbuncle.
Herba speranskiae tuberculatae: expelling wind and removing dampness, removing toxic substances pain relieving.For rheumatic arthritis; Sore swollen toxin is controlled in external.
Radix Glycyrrhizae: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, the anxious pain of gastral cavity abdomen, extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Parthenocissus: dispelling wind and removing obstruction in the collateral, promoting blood circulation and detoxication.For rheumatic arthritis; Traumatic injury is controlled in external, carbuncle furuncle and phyma poison.
Compared with prior art, the present invention has following beneficial effect: the present invention treats the medicine of rheumatic arthritis, its determined curative effect, persistent, non-evident effect.Conciliation function of human body is had while curing the disease, constitutional effect, after taking medicine, patient's limb blood circulation is accelerated, medicine along with blood flowing arrive suffering limb go window-shopping, the precipitate in articular cavity is absorbed by tissue gradually, decomposes, if any nonabsorbable virus, the effect that can also local borrowed slightly to perspire excretes, and eradicates the state of an illness.The preparation method of pharmaceutical composition of the present invention is simple, convenient operation, is easy to grasp.
Detailed description of the invention
Below in conjunction with specific embodiment, the specific embodiment of the present invention is described in detail, but is to be understood that protection scope of the present invention not by the restriction of detailed description of the invention.
Embodiment 1
Prescription one
Herba Rostellulariae 5 parts, Herba Taraxaci 1 part, Herba Dendrobii 5 parts, Formica fusca 1 part, Radix Aconiti Kusnezoffii 5 parts, Herba Lycopodii 5 parts, Olibanum 1 part, Herba polygoni hydropiperis 5 parts and Radix Polygoni Multiflori 1 part.
By the Chinese medicine in prescription one, decoct with water 2 times, add water 3000ml for the first time, decocts 2 hours, filters and obtain filtrate, the 2nd 3000ml that adds water, decoct 2 hours, and decocting liquid filters, and filtrate is merged.Filtrate is concentrated into 1.05 (under 60 DEG C of conditions), adds sodium benzoate and steviosin, mixing leaves standstill, and gets the supernatant, obtains pharmaceutical composition stock solution, add water and make into 1000ml, mixing, fill, sterilizing and get final product.
Embodiment 2
Prescription two
Herba Rostellulariae 7 parts, Herba Taraxaci 4 parts, Herba Dendrobii 7 parts, Formica fusca 2 parts, Radix Aconiti Kusnezoffii 6 parts, Herba Lycopodii 9 parts, Olibanum 2 parts, Herba polygoni hydropiperis 8 parts and Radix Polygoni Multiflori 3 parts.
The preparation method of the medicine of the present embodiment treatment rheumatic arthritis is identical with embodiment 1.
Embodiment 3
Prescription three
Herba Rostellulariae 10 parts, Herba Taraxaci 5 parts, Herba Dendrobii 10 parts, Formica fusca 3 parts, Radix Aconiti Kusnezoffii 10 parts, Herba Lycopodii 15 parts, Olibanum 5 parts, Herba polygoni hydropiperis 10 parts and Radix Polygoni Multiflori 5 parts.
The preparation method of the medicine of the present embodiment treatment rheumatic arthritis is identical with embodiment 1.
Embodiment 4
Herba Rostellulariae 7 parts, Herba Taraxaci 4 parts, Herba Dendrobii 7 parts, Formica fusca 2 parts, Radix Aconiti Kusnezoffii 6 parts, Herba Lycopodii 9 parts, Olibanum 2 parts and Herba polygoni hydropiperis 8 parts.
The preparation method of the medicine of the present embodiment treatment rheumatic arthritis is identical with embodiment 1.
Embodiment 5
Herba Rostellulariae 7 parts, Herba Taraxaci 4 parts, Herba Dendrobii 7 parts, Formica fusca 2 parts, Radix Aconiti Kusnezoffii 6 parts, Herba Lycopodii 9 parts, Olibanum 2 parts, Herba polygoni hydropiperis 8 parts, Radix Polygoni Multiflori 3 parts, 6 parts, Herba speranskiae tuberculatae 10 parts, 3 parts, Radix Glycyrrhizae and parthenocissus 5 parts.
The preparation method of the medicine of the present embodiment treatment rheumatic arthritis is identical with embodiment 1.
Embodiment 6
Herba Rostellulariae 7 parts, Herba Taraxaci 4 parts, Herba Dendrobii 7 parts, Formica fusca 2 parts, Radix Aconiti Kusnezoffii 6 parts, Herba Lycopodii 9 parts, Olibanum 2 parts, Herba polygoni hydropiperis 8 parts, Herba speranskiae tuberculatae 10 parts, 3 parts, Radix Glycyrrhizae and parthenocissus 5 parts.
The preparation method of the medicine of the present embodiment treatment rheumatic arthritis is identical with embodiment 1.
Use Drug therapy rheumatic arthritis of the present invention, this experiment adopts the method for open randomized control study to carry out clinical observation on the therapeutic effect to Chinese medicine composition mixture.
1, experiment is divided into 7 groups, wherein experimental group 6 groups, matched group 1 group.
Experimental group 1,10 people, wherein male 4 people, the age is 30 ~ 50 years old, female 6 people, 33 ~ 55 years old age.Average course of disease 3.7 years.Adopt the medicine that embodiment 1 is obtained.
Experimental group 2,10 people, wherein male 5 people, the age is 34 ~ 54 years old, female 5 people, 26 ~ 55 years old age.Average course of disease 4 years.Adopt the medicine that embodiment 2 is obtained.
Experimental group 3,10 people, wherein male 4 people, the age is 31 ~ 56 years old, female 6 people, 34 ~ 65 years old age.Average course of disease 3.8 years.Adopt the medicine that embodiment 3 is obtained.
Experimental group 4,10 people, wherein male 4 people, the age is 35 ~ 59 years old, female 6 people, 33 ~ 63 years old age.Average course of disease 4.2 years.Adopt the medicine that embodiment 4 is obtained.
Experimental group 5,10 people, wherein male 5 people, the age is 30 ~ 58 years old, female 5 people, 32 ~ 63 years old age.Average course of disease 4.5 years.Adopt the medicine that embodiment 5 is obtained.
Experimental group 6,10 people, wherein male 4 people, the age is 32 ~ 66 years old, female 6 people, 31 ~ 63 years old age.Average course of disease 3.9 years.Adopt the medicine that embodiment 6 is obtained.
Matched group, 10 people, wherein male 4 people, the age is 30 ~ 50 years old, female 6 people, 33 ~ 55 years old age.Average course of disease 4.2 years.
2, diagnostic criteria:
Tcm diagnosis: (1) arthromyodynia: swelling, pain, stiff, joint stuffiness, even arthroncus, distortion, tetanic person occur at the positions such as all joints, muscle, muscles and bones.(2) wind-damp-heat syndrome: joint or muscle local red and swollen, scorching hot, weigh, tactile scorching hot or hotness, feeling thirst but no desire to drink, or have heating, red tongue, a yellow and greasy fur, slippery and rapid pulse or moisten number.
Western medicine diagnose: all meet wherein 4 diagnosable for rheumatoid arthritis:
(1) refuse to budge morning continuous more than 1h (at least 6 week)
(2) three or more than three arthroncuss (at least 6 week)
(3) arthritis symmetry (at least 6 week)
(4) wrist, the palm refer to, proximal interphalangeal joint swelling (at least 6 week)
(5) x-ray of typical hand changes
(6) the serum rheumatoid factor (SRF) positive (titre exceedes normal peak)
(7) subcutaneous nodule
3, inclusive criteria
(1) Western medicine diagnose standard and Standards of Chinese Medical Syndrome Differentiation value is met
(2) the rheumatic arthritis patient of health ministry new drug clinical criteria is met.
4, exclusion standard:
(1) gestation or women breast-feeding their children
(2) hypertension, conscience kidney hemopoietic system serious disease is associated with, psychotic, digestive tract ulcer Recent Activity bleeder
(3) long-term steroid person
(4) to Chinese medicine composition mixture allergy sufferers.
5, Therapeutic Method
Experimental group takes Chinese medicine composition of the present invention, three times on the one, and each 15ml is oral, and the course for the treatment of is 3 months.Matched group is the medicine of conventional therapy rheumatoid arthritis, and the course for the treatment of is 3 months.
6, observation index
Clinical symptoms, sign: stiff time in morning, arthralgia, arthroncus, joint allomeric function, grip.
Rationality index: C reactive protein, erythrocyte sedimentation rate (before and after treatment respectively once)
Safety indexes: blood, routine urinalysis and hepatic and renal function (before and after treatment respectively once);
Efficacy assessment standard
Clinical disease standards of grading:
Classification record is given to local joint symptom, joint stiff time in morning, arthralgia index, joint swelling index.(note: index is affected joints number × integration number sum)
Standards of grading are as follows:
(1) the stiff time in morning:
0 point: stiff without morning
1 point: morning, deadlock was less than 30 minutes
2 points: morning, deadlock was less than 60 minutes
3 points: morning, deadlock was greater than 60 minutes
(2) arthralgia integration:
0 point: without pain
1 point: mild pain, during compressing, tell pain
2 points: moderate pain, during compressing, aobvious painful expression, shrinks back, does not affect sleep
3 points: severe pain, the inspection of refusal tenderness, impact sleep.
(3) arthroncus integration:
0 point: without swelling
1 point: mild swelling, swelling goes out position lower than neighbouring apophysis
2 points: moderate swelling, swelling and neighbouring apophysis go out position puts down
3 points: severe swelling, swelling exceeds neighbouring apophysis and goes out position.
Note: integral and calculating: integration summation * 100% before (before treatment the rear integration summation of integration summation-treatment)/treatment, erythrocyte sedimentation rate calculates: (after the front value-treatment for the treatment of value)/(before treating value-normal value) * 100%; Be added after calculating the improvement percent of indices and calculate its average percentage to judge curative effect.
General curative effect standard
Effective: after observation index treatment, integration summation declines >=70% than integration summation before treatment
Effective: after observation index treatment, integration summation is than integration summation decline >=50%-< 70% before treatment
Improve: after observation index treatment, integration summation is than integration summation decline >=30%-< 50% before treatment
Invalid: after observation index treatment, integration summation is than integration summation decline < 30% before treatment
Note: integral and calculating: integration summation * 100% before (before treatment the rear integration summation of integration summation-treatment)/treatment.
Statistical procedures method:
According to data different in kind, adopt the analytical methods such as t inspection, X 2 test respectively, data result X ± SD shows
Result
Before and after two groups of Drug therapys morning deadlock, arthralgia, swelling, grip and joint allomeric function change (X ± SD).
Table 1 is the change list of deadlock in morning
| Group | Number of cases | Before treatment | After treatment |
| Experimental group 1 | 10 | 131.28±54.02 | 51.28±35.26 *** |
| Experimental group 2 | 10 | 132.78±54.34 | 51.98±35.16 *** |
| Experimental group 3 | 10 | 130.98±55.08 | 51.98±35.56 *** |
| Experimental group 4 | 10 | 130.88±54.08 | 55.98±56.26 *** |
| Experimental group 5 | 10 | 133.68±53.08 | 50.68±35.56 *** |
| Experimental group 6 | 10 | 132.98±55.18 | 55.78±56.66 *** |
| Matched group | 10 | 119.87±75.30 | 58.95±65.08 ** |
Note: compared with before treatment:
*p < 0.01,
* *p < 0.001
Table 2 is the change list of arthralgia index
| Group | Number of cases | Before treatment | After treatment |
| Experimental group 1 | 10 | 15.82±5.10 | 7.84±4.23 *** |
| Experimental group 2 | 10 | 15.92±5.40 | 7.74±4.13 *** |
| Experimental group 3 | 10 | 15.72±6.10 | 7.94±4.53 *** |
| Experimental group 4 | 10 | 16.82±7.11 | 8.94±5.33 *** |
| Experimental group 5 | 10 | 17.34±6.32 | 6.64±4.33 *** |
| Experimental group 6 | 10 | 16.72±6.10 | 8.84±6.23 *** |
| Matched group | 10 | 17.21±10.08 | 9.88±6.61 ** |
Compared with before treatment: * * P < 0.01, * * * P < 0.001
Table 3 is the change list of joint swelling index
| Group | Number of cases | Before treatment | After treatment |
| Experimental group 1 | 10 | 11.78±5.05 | 5.14±4.01 *** |
| Experimental group 2 | 10 | 12.88±5.10 | 5.44±4.03 *** |
| Experimental group 3 | 10 | 13.11±5.13 | 5.32±4.13 *** |
| Experimental group 4 | 10 | 13.64±4.68 | 6.68±5.24 *** |
| Experimental group 5 | 10 | 12.89±5.08 | 5.16±4.01 *** |
| Experimental group 6 | 10 | 13.98±4.76 | 6.33±5.02 *** |
| Matched group | 10 | 16.10±9.81 | 7.86±6.41 ** |
Compared with before treatment: * * P < 0.01, * * * P < 0.001.
Table 4 is the change list of erythrocyte sedimentation rate
| Group | Number of cases | Before treatment | After treatment |
| Experimental group 1 | 10 | 57.96±22.24 | 33.85±20.27 *** |
| Experimental group 2 | 10 | 57.63±23.17 | 34.18±21.27 *** |
| Experimental group 3 | 10 | 56.76±21.14 | 32.97±21.19 *** |
| Experimental group 4 | 10 | 57.78±22.69 | 35.76±25.25 *** |
| Experimental group 5 | 10 | 57.52±22.68 | 31.74±19.33 *** |
| Experimental group 6 | 10 | 58.22±22.30 | 35.64±25.23 *** |
| Matched group | 10 | 49.61±22.51 | 34.38±20.21 ** |
Note: compared with before treatment: * * P < 0.05, * * * P < 0.001.
Table 4 is the change list of C reactive protein
| Group | Number of cases | Before treatment | After treatment |
| Experimental group 1 | 10 | 9.80±16.12 | 4.98±8.33 |
| Experimental group 2 | 10 | 9.53±15.51 | 4.84±8.17 |
| Experimental group 3 | 10 | 9.88±16.07 | 5.00±8.03 |
| Experimental group 4 | 10 | 9.74±15.74 | 5.11±9.64 |
| Experimental group 5 | 10 | 9.67±15.94 | 4.72±7.92 |
| Experimental group 6 | 10 | 9.84±16.01 | 5.13±9.55 |
| Matched group | 10 | 8.34±18.23 | 5.37±11.00 |
Note: compared with before treatment: * * P < 0.05, * * * P < 0.001.
As seen from the above comparison, Drug therapy of the present invention, it is evident in efficacy.
The aforementioned description to concrete exemplary of the present invention is to illustrate and the object of illustration.These descriptions not want the present invention to be defined as disclosed precise forms, and obviously, according to above-mentioned instruction, can much change and change.The object selected exemplary embodiment and describe is to explain certain principles of the present invention and practical application thereof, thus those skilled in the art can be realized and utilize various different exemplary of the present invention and various different selection and change.Scope of the present invention is intended to limited by claims and equivalents thereof.
Claims (10)
1. treat a medicine for rheumatic arthritis, it is characterized in that, it contains pharmaceutically acceptable carrier or excipient, and following active component: Herba Rostellulariae, Herba Taraxaci, Herba Dendrobii, Formica fusca, Radix Aconiti Kusnezoffii, Herba Lycopodii, Olibanum, Herba polygoni hydropiperis and Radix Polygoni Multiflori.
2. treat the medicine of rheumatic arthritis according to claim 1, it is characterized in that, it contains pharmaceutically acceptable carrier or excipient, and the active component of following weight ratio: Herba Rostellulariae 5 ~ 10 parts, Herba Taraxaci 1 ~ 5 part, Herba Dendrobii 5 ~ 10 parts, Formica fusca 1 ~ 3 part, Radix Aconiti Kusnezoffii 5 ~ 10 parts, Herba Lycopodii 5 ~ 15 parts, Olibanum 1 ~ 5 part, Herba polygoni hydropiperis 5 ~ 10 parts and Radix Polygoni Multiflori 1 ~ 5 part.
3. treat the medicine of rheumatic arthritis according to claim 2, it is characterized in that, it contains pharmaceutically acceptable carrier or excipient, and the active component of following weight ratio: Herba Rostellulariae 7 parts, Herba Taraxaci 4 parts, Herba Dendrobii 7 parts, Formica fusca 2 parts, Radix Aconiti Kusnezoffii 6 parts, Herba Lycopodii 9 parts, Olibanum 2 parts, Herba polygoni hydropiperis 8 parts and Radix Polygoni Multiflori 3 parts.
4. treat the medicine of rheumatic arthritis according to claim 2, it is characterized in that, described pharmaceutical composition also comprises following active component:, Herba speranskiae tuberculatae, Radix Glycyrrhizae and parthenocissus.
5. treat the medicine of rheumatic arthritis according to claim 4, it is characterized in that, described pharmaceutical composition also comprises the active component of following weight ratio: Herba speranskiae tuberculatae 5 ~ 15 parts, 1 ~ 5 part, Radix Glycyrrhizae and parthenocissus 2 ~ 8 parts.
6. treat the medicine of rheumatic arthritis according to claim 1, it is characterized in that, the dosage form of described pharmaceutical composition is selected from: mixture, ointment, preparation capable of permeating skin, externally used solution agent, lotion, smear agent, ointment, plaster, paste or patch.
7. treat the medicine of rheumatic arthritis according to claim 1, it is characterized in that, described pharmacy and bromatology can be selected from by carrier: filler, lubricant, fluidizer, effervescent, correctives, coating material or excipient.
8. treat the preparation method of the medicine of rheumatic arthritis as claimed in claim 1 for one kind, it is characterized in that, by Herba Rostellulariae, Herba Taraxaci, Herba Dendrobii, Formica fusca, Radix Aconiti Kusnezoffii, Herba Lycopodii, Olibanum, Herba polygoni hydropiperis and Radix Polygoni Multiflori mixing, decoct with water 1 ~ 3 hour, decocting liquid filters, and filtrate is concentrated into 1.00 ~ 1.10, add stabilizing agent, mixing leaves standstill, and gets the supernatant, obtains pharmaceutical composition stock solution.
9. treat the preparation method of the medicine of rheumatic arthritis according to claim 8, it is characterized in that, in described preparation method, decoct with water 2 times, decoct 1 ~ 3 hour at every turn, then twice decoction is obtained filtrate mixing.
10. treat the preparation method of the medicine of rheumatic arthritis according to claim 8, it is characterized in that, described stabilizing agent is one or both in sodium benzoate or steviosin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510670431.3A CN105250721A (en) | 2015-10-16 | 2015-10-16 | Medicine for treating rheumatoid arthritis and preparation method of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510670431.3A CN105250721A (en) | 2015-10-16 | 2015-10-16 | Medicine for treating rheumatoid arthritis and preparation method of medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250721A true CN105250721A (en) | 2016-01-20 |
Family
ID=55090849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510670431.3A Pending CN105250721A (en) | 2015-10-16 | 2015-10-16 | Medicine for treating rheumatoid arthritis and preparation method of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250721A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648528A (en) * | 2017-11-24 | 2018-02-02 | 福建拓天生物科技有限公司 | A kind of Chinese medicine composition containing dendrobium candidum and preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406532A (en) * | 2008-11-18 | 2009-04-15 | 陈玲 | Medicament for mainly curing rheumatism |
| CN102526172A (en) * | 2012-03-21 | 2012-07-04 | 河南省洛正制药厂 | Chinese medicinal bagged soaking agent for treating joint numbness pain and preparation method thereof |
| CN103893574A (en) * | 2014-03-14 | 2014-07-02 | 于波 | Traditional Chinese medicine powder for treating rheumatic arthritis |
-
2015
- 2015-10-16 CN CN201510670431.3A patent/CN105250721A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406532A (en) * | 2008-11-18 | 2009-04-15 | 陈玲 | Medicament for mainly curing rheumatism |
| CN102526172A (en) * | 2012-03-21 | 2012-07-04 | 河南省洛正制药厂 | Chinese medicinal bagged soaking agent for treating joint numbness pain and preparation method thereof |
| CN103893574A (en) * | 2014-03-14 | 2014-07-02 | 于波 | Traditional Chinese medicine powder for treating rheumatic arthritis |
Non-Patent Citations (2)
| Title |
|---|
| 潘义民: "《常见病症家庭食疗与验方》", 31 March 1996 * |
| 潘青海: "《中医学》", 31 October 1991 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648528A (en) * | 2017-11-24 | 2018-02-02 | 福建拓天生物科技有限公司 | A kind of Chinese medicine composition containing dendrobium candidum and preparation method and application |
| CN107648528B (en) * | 2017-11-24 | 2021-04-13 | 福建拓天生物科技有限公司 | Traditional Chinese medicine composition containing dendrobium officinale and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100376276C (en) | Soothe tendons and activating-blood anodyne plaster | |
| CN104189871A (en) | Medicated wine for treating osteoproliferation | |
| CN101181568A (en) | Traditional chinese medicine preparation for curing osteoproliferation as well as arthrosis ache | |
| CN102475868B (en) | Anti-rheumatism medicinal liquor | |
| CN103463580B (en) | Chinese medicine ointment for treating pain of muscles, bones and joints and preparation method thereof | |
| CN103908600B (en) | The external used medicine for the treatment of rheumatoid arthritis damp-heat arthralgia resistance card and preparation method | |
| CN103191330B (en) | Traditional Chinese medicine used for treating swelling of limbs of hemiplegic patient | |
| CN105250721A (en) | Medicine for treating rheumatoid arthritis and preparation method of medicine | |
| CN104162088A (en) | Traditional Chinese medicine composition for relieving rigidity of muscles, activating collaterals and eliminating dampness and preparation method thereof | |
| CN104491828B (en) | A kind of temperature leads to Traditional Chinese medicine used as analgesic preparation and its paste preparation method | |
| CN1309406C (en) | Medicinal preparation for treating rheumatism and rheumatoid diseases | |
| CN105770847A (en) | Traditional Chinese medicine composition for relieving or treating joint swelling and pain and preparation method and application of traditional Chinese medicine composition | |
| CN105012594A (en) | Traditional Chinese medicine for treating knee osteoarthritis | |
| CN104800443A (en) | Bone setting agent with functions of tonifying kidney and regenerating bone marrow | |
| CN105213514A (en) | Pharmaceutical composition for the treatment of rheumatoid arthritis and preparation method thereof | |
| CN102225130B (en) | Traditional Chinese medicine compound for treating rheumatoid arthritis and preparation method thereof | |
| CN102861195B (en) | Drug composition for treating rheumatism pain | |
| CN110893206B (en) | Externally applied medicine for treating rheumatic arthritis and preparation method thereof | |
| CN102028916B (en) | Thickleaf croton root and clematis root soup for treating lumbocrural pain | |
| CN104547086A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN104189866A (en) | Externally-used traditional Chinese medicine wine for treating knee joint bone hyperplasia | |
| CN117982573A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method and application thereof | |
| CN105327144A (en) | Traditional Chinese medicine for treating knee osteoarthritis | |
| CN104383424A (en) | Pharmaceutical composition for promoting fracture healing | |
| CN103599294B (en) | Traditional Chinese medicine liquid extract for treating ankylosing spondylitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160120 |